Jose Calle Gordo

Jose Calle Gordo serves as Vice Chairman at Biosensors International Group and previously served as its Chief Executive Officer. He serves as Board Member at JenaValve Technology. Gordo also serves as Advisory Board Member at Thuja Capital Management. Mr Jose Calle Gordo joined Biosensors on 1 September 2014 as the Chief Executive Officer and was appointed as an Executive Director on 8 October 2014. He had a successful career with over 25 years of broad business and management experience in the medical devices industry, having served in various vice president and managerial roles at Abbott, Guidant and Eli Lilly. He led the global team that developed and commercialized Xience, a family of drug eluting stents (DES) and market leader for the treatment of coronary artery disease while serving as Vice President and General Manager of Drug Eluting Stents, Vascular Intervention at Guidant based in Santa Clara, California (US). As Vice President of Abbott Vascular based in Brussels, he later managed the international operations of Abbott Vascular outside of the US and more recently he led globally the commercial introduction of bioresorbable vascular scaffolds (ABSORB BVS) and MitraClip, the world's first percutaneous mitral valve repair therapy. During his earlier years with Guidant and Eli Lilly, he contributed in different managerial roles to the commercial and therapy development of the implanted defibrillator and cardiac resynchronization therapy. Calle Gordo received his Biomedical/Medical Engineering (Electrical Engineering) degree from Universidad Politecnica de Madrid, Spain. He serves as Senior Advisor at Hadean Ventures.